Study demonstrates effectiveness of ferric maltol

RNS Number : 5235T

Shield Therapeutics PLC

26 March 2021

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Study demonstrates real-world effectiveness of ferric maltol

Clinical collaborators publish results from FRESH study in BMJ Open Gastroenterology

London, UK, 26 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes the recent publication in BMJ Open Gastroenterology, titled: "Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK."

The study details the positive results from a real-world study using ferric maltol to assess clinical characteristics and outcomes of patients with inflammatory bowel disease (IBD) receiving ferric maltol for iron-deficiency anaemia in the UK (FRESH Study).

The observational, multicentre study, retrospective cohort study included adults with IBD and iron-deficiency anaemia (IDA) and who also had serum ferritin levels below 30 μg/L or transferrin saturation  below 20%, who received ferric maltol.  The study concluded that ferric maltol increases haemoglobin and iron indices and is generally well tolerated in patients with IBD and IDA treated in clinical practice.  These real-world data confirm the favourable benefit/risk balance findings from randomised control trials.

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO)
Peel Hunt LLP - Nominated Adviser and Joint Broker			[phone]
James Steel / Christopher Golden
finnCap Ltd - Joint Broker	[phone]
Geoff Nash / Alice Lane / Matthew Radley
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

NRAPPUMWWUPGGPA